Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Caribou Biosciences, Inc.NASDAQ: CRBU

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow declines year over year

Q1 FY2026 investing cash flow of $23.99M fell 51.4% year over year, behind the -32.0% change in trailing-twelve-month investing cash flow. Sequentially, it rose 33.5% from the prior quarter.

Context

  • Investing cash flow amounted to 916.2% of revenue in FY2025, up 49.6 pp from a year earlier.
  • Investing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -51.4% toward the trailing-twelve-month pace of -32.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.99M+33.5% QoQ
Last fiscal yearDec 2025
$102.24M+18.0% YoY
LTMMar 2026
$76.84M-32.0% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-51.4%——
1 year+18.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
102.24M USD
Year-over-year change
+18.0%

Investing Cash Flow vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.0% is the 6th highest of 11, against a peer median of -20.5%.
  • Investing cash flow amounts to 685.9% of revenue for CRBU, versus a peer median of 160.3%.
CRBU Competitors
Investing Cash Flow for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€127.93M EUR-1562.9%—2853.7%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$97.21M USD+178.0%+267.6%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$76.84M USD-32.0%—685.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$64.92M USD+335.2%—230.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$59.8M USD+0.1%-3.4%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$59.54M USD-177.1%-9.8%86.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$59.41M USD+39.9%—428.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$33.77M USD+20.9%-12.5%15008.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$29.62M USD-246.4%-25.1%90.5%
HUMAHumacyte, Inc.LTM Mar 2026$831K USD-41.0%—41.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$228K USD-100.2%-13.2%1.4%
Peer median (excluding CRBU) —-20.5%-11.1%160.3%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
Deferred Income Tax0(95K)00(548K)
Stock-Based Compensation3.45M11.72M13.75M16.71M12.68M
Change in Working Capital29.07M(4.11M)(7.32M)(5.11M)(484K)
Accounts Receivables(2.96M)3.46M805K608K272K
Inventory00000
Accounts Payables1.14M(2.72M)1.82M(354K)3.25M
Other Working Capital30.89M(4.85M)(9.94M)(5.37M)(4.01M)
Other Non-Cash Items904K9.02M(1.18M)(4.61M)21.84M
Operating Cash Flow(32.52M)(90.97M)(93.29M)(138.2M)(110.99M)
Capital Expenditures(3.12M)(6.45M)(11.61M)(6.51M)(1.36M)
Acquisitions (Net)00000
Purchases of Investments(173.28M)(339.06M)(394.76M)(304.39M)(150.37M)
Sales of Investments0252.87M338.19M397.49M252.83M
Other Investing Activities(1M)(600K)0(1.61M)1.14M
Investing Cash Flow(176.4M)(93.25M)(68.18M)86.61M102.24M
Debt Repayment1.03M0000
Common Stock Issued321.02M2.13M152.72M15.19M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.55M01.58M1.53M0
Financing Cash Flow433.43M2.13M154.3M16.72M4.82M
Effect of Forex Changes00000
Net Change in Cash224.51M(182.08M)(7.18M)(34.87M)(3.93M)
Free Cash Flow(35.64M)(97.42M)(104.9M)(144.71M)(112.35M)

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.